Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprotinin versus placebo during lung or esophageal cancer surgery
ACTRN12606000314527Phase 3Terminated
- Sponsor
- Bayer
- Start
- Dec 2005
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bronchial carcinoma and esophageal cancer comparing Trasylol with Placebo (2 arms). Primary endpoint: Need for blood transfusion. Started Dec 2005; status: terminated.
02
Drugs
aprotinin
03
Conditions
bronchial carcinomaesophageal cancer
Beyond the preview
Go deeper on ACTRN12606000314527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000314527.